Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Fast nonadiabatic dynamics of many-body quantum systems.

Larder B, Gericke DO, Richardson S, Mabey P, White TG, Gregori G.

Sci Adv. 2019 Nov 22;5(11):eaaw1634. doi: 10.1126/sciadv.aaw1634. eCollection 2019 Nov.

2.

Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Tempelman H, Clotet B, Reiss P, van Sighem AI, Alvarez-Uria G, Nelson M, Montaner JSG, Lane HC, Larder BA.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):207-215. doi: 10.1097/QAI.0000000000001989.

PMID:
30865186
3.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Rehm CA, Pozniak A, Montaner JSG, Lane HC, Larder BA; RDI Data and Study Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2186-2196. doi: 10.1093/jac/dky179.

4.

Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa.

Revell A, Khabo P, Ledwaba L, Emery S, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem A, Pozniak A, Montaner J, Lane HC, Larder B.

South Afr J HIV Med. 2016 Jun 30;17(1):450. doi: 10.4102/sajhivmed.v17i1.450. eCollection 2016.

5.

An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Nelson M, Montaner JS, Lane HC, Larder BA; RDI Data and Study Group.

J Antimicrob Chemother. 2016 Oct;71(10):2928-37. doi: 10.1093/jac/dkw217. Epub 2016 Jun 20.

6.

A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.

Revell AD, Boyd MA, Wang D, Emery S, Gazzard B, Reiss P, van Sighem AI, Montaner JS, Lane HC, Larder BA.

HIV Med. 2014 Aug;15(7):442-8. doi: 10.1111/hiv.12156. Epub 2014 Apr 15.

7.

An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers R, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing A, Reiss P, van Sighem AI, Nelson M, Emery S, Montaner JS, Lane HC, Larder BA; RDI Study Group.

J Antimicrob Chemother. 2014 Apr;69(4):1104-10. doi: 10.1093/jac/dkt447. Epub 2013 Nov 24.

8.

Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.

Revell AD, Alvarez-Uria G, Wang D, Pozniak A, Montaner JS, Lane HC, Larder BA.

Biomed Res Int. 2013;2013:579741. doi: 10.1155/2013/579741. Epub 2013 Sep 24.

9.

Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.

Revell AD, Wang D, Wood R, Morrow C, Tempelman H, Hamers RL, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing AM, DeWolf F, Nelson M, Montaner JS, Lane HC, Larder BA; RDI study group.

J Antimicrob Chemother. 2013 Jun;68(6):1406-14. doi: 10.1093/jac/dkt041. Epub 2013 Mar 13.

10.

The use of computational models to predict response to HIV therapy for clinical cases in Romania.

Revell AD, Ene L, Duiculescu D, Wang D, Youle M, Pozniak A, Montaner J, Larder BA.

Germs. 2012 Mar 1;2(1):6-11. doi: 10.11599/germs.2012.1007. eCollection 2012 Mar 1.

11.

The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool.

Revell AD, Wang D, Boyd MA, Emery S, Pozniak AL, De Wolf F, Harrigan R, Montaner JS, Lane C, Larder BA; RDI Study Group.

AIDS. 2011 Sep 24;25(15):1855-63. doi: 10.1097/QAD.0b013e328349a9c2.

PMID:
21785323
12.

HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies.

Mascolini M, Mellors JW, Richman DD, Boucher CA, Larder BA.

Antivir Ther. 2011;16(2):263-86. doi: 10.3851/IMP1761.

PMID:
21447877
13.

Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience.

Larder BA, Revell A, Mican JM, Agan BK, Harris M, Torti C, Izzo I, Metcalf JA, Rivera-Goba M, Marconi VC, Wang D, Coe D, Gazzard B, Montaner J, Lane HC.

AIDS Patient Care STDS. 2011 Jan;25(1):29-36. doi: 10.1089/apc.2010.0254.

14.

Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings.

Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM, Dewolf F, Nelson M, Geretti AM, Larder BA.

J Antimicrob Chemother. 2010 Apr;65(4):605-7. doi: 10.1093/jac/dkq032. Epub 2010 Feb 12. Review.

15.

Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop.

Mascolini M, Boucher CA, Mellors JW, Larder BA, Richman DD.

Antivir Ther. 2009;14(7):1015-37. doi: 10.3851/IMP1423.

PMID:
19918107
16.

A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy.

Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, D'Arminio Monforte A, Torti C, Zazzi M, Lane C.

Artif Intell Med. 2009 Sep;47(1):63-74. doi: 10.1016/j.artmed.2009.05.002. Epub 2009 Jun 12.

PMID:
19524413
17.

Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop.

Mascolini M, Larder BA, Boucher CA, Richman DD, Mellors JW.

Antivir Ther. 2008;13(8):1097-113.

PMID:
19195337
18.

Application of artificial neural networks for decision support in medicine.

Larder B, Wang D, Revell A.

Methods Mol Biol. 2008;458:123-36.

PMID:
19065808
19.

Clinical implications of resistance to antiretrovirals: new resistance technologies and interpretations.

Mascolini M, Richman D, Larder B, Mellors J, Boucher CA.

Antivir Ther. 2008;13(2):319-34.

PMID:
18505183
20.

Key reports from the XV International HIV Drug Resistance Workshop 2006.

Mascolini M, Boucher C, Larder B, Mellors J, Richman D.

Antivir Ther. 2007;12(1):131-45.

PMID:
17503758
21.

The development of artificial neural networks to predict virological response to combination HIV therapy.

Larder B, Wang D, Revell A, Montaner J, Harrigan R, De Wolf F, Lange J, Wegner S, Ruiz L, Pérez-Elías MJ, Emery S, Gatell J, Monforte AD, Torti C, Zazzi M, Lane C.

Antivir Ther. 2007;12(1):15-24.

PMID:
17503743
22.

The XIVth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005.

Boucher C, Larder B, Mellors J, Richman D.

Antivir Ther. 2006;11(5):653-65.

PMID:
16964836
24.

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial.

Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL; RV-125 Centers for Education and Research on Therapeutics Study Team.

Clin Infect Dis. 2004 Mar 1;38(5):723-30. Epub 2004 Feb 6.

PMID:
14986258
25.

Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.

Harrigan PR, Hertogs K, Verbiest W, Larder B, Yip B, Brumme ZL, Alexander C, Tilley J, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):395-402.

PMID:
14640386
26.

Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.

Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E.

AIDS. 2003 Jul;17 Suppl 3:S39-48.

PMID:
14565608
27.

Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

Adjé-Touré C, Celestin B, Hanson D, Roels TH, Hertogs K, Larder B, Diomande F, Peeters M, Eholié S, Lackritz E, Chorba T, Nkengasong JN.

AIDS. 2003 Jul;17 Suppl 3:S23-9.

PMID:
14565606
28.

Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.

DiRienzo AG, DeGruttola V, Larder B, Hertogs K.

Stat Med. 2003 Sep 15;22(17):2785-98.

PMID:
12939786
29.

Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.

Wang D, Larder B.

J Infect Dis. 2003 Sep 1;188(5):653-60. Epub 2003 Aug 14.

PMID:
12934180
32.

Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215.

Chamberlain PP, Ren J, Nichols CE, Douglas L, Lennerstrand J, Larder BA, Stuart DI, Stammers DK.

J Virol. 2002 Oct;76(19):10015-9.

33.

Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991.

Easterbrook PJ, Hertogs K, Waters A, Wills B, Gazzard BG, Larder B.

J Infect. 2002 Feb;44(2):88-91.

PMID:
12076067
34.
35.

Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M.

J Infect Dis. 2002 Apr 1;185(7):898-904. Epub 2002 Mar 11.

PMID:
11920313
36.

Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.

Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA.

Antimicrob Agents Chemother. 2002 Apr;46(4):1067-72.

37.
38.

Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.

Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H, Nagai Y.

Antimicrob Agents Chemother. 2002 Mar;46(3):708-15.

39.

Mechanisms of HIV-1 drug resistance.

Larder B.

AIDS. 2001;15 Suppl 5:S27-34. Review. No abstract available.

PMID:
11816171
40.

Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1.

Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W.

J Clin Microbiol. 2002 Jan;40(1):31-5.

41.

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

Middleton T, Smith D, Larder B, Law M, Birch C.

HIV Clin Trials. 2001 Nov-Dec;2(6):445-52.

PMID:
11742431
42.

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, Larder B, Dewar RL, Fox CH, Hallahan CW, Justement JS, Migueles SA, Metcalf JA, Davey RT, Daucher M, Pandya P, Baseler M, Ward DJ, Fauci AS.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6. Epub 2001 Dec 4.

43.

Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART.

Caride E, Hertogs K, Larder B, Dehertogh P, Brindeiro R, Machado E, de Sá CA, Eyer-Silva WA, Sion FS, Passioni LF, Menezes JA, Calazans AR, Tanuri A.

Virus Genes. 2001;23(2):193-202.

PMID:
11724274
44.

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

Ross L, Liao Q, Gao H, Pham S, Tolson J, Hertogs K, Larder B, Saag MS.

AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1379-85.

PMID:
11679150
45.
46.

Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

Miller MD, Margot NA, Hertogs K, Larder B, Miller V.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):1025-8.

PMID:
11562951
47.

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.

Peters S, Muñoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P, Telenti A.

J Virol. 2001 Oct;75(20):9644-53.

48.

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA.

AIDS. 2001 Sep 7;15(13):1671-7.

PMID:
11546942
50.

Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.

Vandamme AM, Houyez F, Bànhegyi D, Clotet B, De Schrijver G, De Smet KA, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman R, Schulse E, Sönnerborg A, Miller V.

Antivir Ther. 2001 Mar;6(1):21-39. Review.

PMID:
11417759

Supplemental Content

Loading ...
Support Center